Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
InMed Pharmaceuticals Inc. is a biopharmaceutical company operating in the cannabinoid-based therapeutics and specialty chemical manufacturing industries. The company focuses on the research, development, and commercialization of rare cannabinoids as pharmaceutical drug candidates, as well as the production and sale of pharmaceutical‑grade cannabinoid ingredients. Its operations span drug discovery and development, biosynthetic manufacturing, and business‑to‑business ingredient supply.
The company’s primary activities are divided between clinical‑stage pharmaceutical development targeting diseases with high unmet medical need and the commercial manufacturing of rare cannabinoids for third‑party customers. InMed serves pharmaceutical, health and wellness, and specialty ingredient customers, with a strategic emphasis on rare cannabinoids that are difficult to source at scale. Its positioning is supported by proprietary biosynthesis technology and an integrated approach that combines drug development with commercial manufacturing. Founded in 1981 and later repositioned to focus on cannabinoids, InMed evolved significantly in the mid‑2010s as cannabinoid science gained regulatory and commercial momentum, culminating in the acquisition of a U.S.-based manufacturing platform.
Business Operations
InMed operates through two primary business segments: Pharmaceutical Research and Development and Cannabinoid Manufacturing and Sales. The pharmaceutical segment is focused on developing cannabinoid‑based drug candidates, including INM‑755, a cannabinol (CBN) cream being investigated for the treatment of epidermolysis bullosa, and other preclinical programs targeting glaucoma and inflammatory conditions. These programs are internally developed and supported by proprietary intellectual property.
The manufacturing and commercial segment is conducted through BayMedica LLC, a wholly owned subsidiary that produces rare cannabinoids using biosynthesis and chemical synthesis technologies. BayMedica supplies bulk rare cannabinoids, including CBN and other minor cannabinoids, to third‑party customers globally. Operations include U.S.-based manufacturing assets, formulation capabilities, and sales to pharmaceutical and wellness ingredient markets. The company does not currently rely on material joint ventures but maintains commercial relationships with ingredient customers and research collaborators.
Strategic Position & Investments
InMed’s strategic direction centers on advancing late preclinical and clinical drug candidates while expanding revenue from rare cannabinoid manufacturing. Growth initiatives include progressing INM‑755 through clinical development, broadening the portfolio of biosynthetically produced cannabinoids, and increasing commercial penetration of high‑purity ingredients. The company positions itself at the intersection of pharmaceutical development and scalable cannabinoid production, which it views as a long‑term competitive advantage.
A major strategic investment was the acquisition of BayMedica LLC, which significantly expanded InMed’s capabilities in rare cannabinoid biosynthesis and provided a near‑term revenue stream to complement its drug development pipeline. The company continues to invest in emerging cannabinoid science, including novel delivery methods and new therapeutic targets, while maintaining capital discipline consistent with a clinical‑stage biotechnology company.
Geographic Footprint
InMed Pharmaceuticals Inc. is headquartered in Canada, with its principal executive offices in British Columbia. Its manufacturing and commercial operations are primarily based in the United States, where BayMedica LLC operates production and sales activities.
The company maintains a market presence in North America and supplies cannabinoid ingredients to customers in Europe and other international markets. While its pharmaceutical development activities are largely centralized, its commercial manufacturing business provides InMed with international reach and exposure to global cannabinoid ingredient demand.
Leadership & Governance
InMed is led by an executive team with experience in biotechnology, pharmaceuticals, and cannabinoid science. Leadership emphasizes disciplined capital allocation, development of proprietary intellectual property, and the dual‑track strategy of pharmaceutical innovation and commercial manufacturing.
Key executives include:
- Eric A. Adams – President & Chief Executive Officer
- Mauro Manca, Ph.D. – Senior Vice President, Research & Development
- John L. Carson – Chief Financial Officer (data inconclusive based on available public sources regarding tenure continuity)
The company is governed by a board of directors overseeing regulatory compliance, strategic execution, and shareholder interests, consistent with requirements of U.S. and Canadian public company reporting frameworks.